GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GNI Group Ltd (FRA:3G6) » Definitions » Cyclically Adjusted Price-to-FCF

GNI Group (FRA:3G6) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to . Start your Free Trial

What is GNI Group Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


GNI Group Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for GNI Group's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GNI Group Cyclically Adjusted Price-to-FCF Chart

GNI Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 1,218.61 -

GNI Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,384.08 - - - -

Competitive Comparison of GNI Group's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, GNI Group's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GNI Group's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GNI Group's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where GNI Group's Cyclically Adjusted Price-to-FCF falls into.


;
;

GNI Group Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

GNI Group's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, GNI Group's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.082/111.1000*111.1000
=-0.082

Current CPI (Mar. 2025) = 111.1000.

GNI Group Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -0.038 98.400 -0.043
201509 -0.034 98.500 -0.038
201512 0.010 98.100 0.011
201603 -0.054 97.900 -0.061
201606 -0.056 98.100 -0.063
201609 -0.013 98.000 -0.015
201612 -0.005 98.400 -0.006
201703 -0.013 98.100 -0.015
201706 -0.050 98.500 -0.056
201709 -0.077 98.800 -0.087
201712 0.009 99.400 0.010
201803 0.025 99.200 0.028
201806 -0.066 99.200 -0.074
201809 -0.027 99.900 -0.030
201812 0.026 99.700 0.029
201903 -0.008 99.700 -0.009
201906 0.029 99.800 0.032
201909 0.013 100.100 0.014
201912 0.001 100.500 0.001
202003 0.088 100.300 0.097
202006 0.028 99.900 0.031
202009 0.077 99.900 0.086
202012 -0.005 99.300 -0.006
202103 0.234 99.900 0.260
202106 -0.081 99.500 -0.090
202109 -0.101 100.100 -0.112
202112 -0.069 100.100 -0.077
202203 0.020 101.100 0.022
202206 -0.043 101.800 -0.047
202209 -0.170 103.100 -0.183
202212 -0.032 104.100 -0.034
202303 0.036 104.400 0.038
202306 -0.055 105.200 -0.058
202309 0.371 106.200 0.388
202312 0.218 106.800 0.227
202403 -0.077 107.200 -0.080
202406 -0.181 108.200 -0.186
202409 -0.133 108.900 -0.136
202412 -0.174 110.700 -0.175
202503 -0.082 111.100 -0.082

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


GNI Group  (FRA:3G6) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


GNI Group Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of GNI Group's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


GNI Group Business Description

Industry
Traded in Other Exchanges
Address
Shinjuku Park Tower, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, JPN, 163-1030
GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases.

GNI Group Headlines

No Headlines